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“Abstract.” Neurodegenerative diseases are becoming prevalent pathologies in 
developed societies due to increasing average of life expectancy of the population. This 
fact has encouraged an active research in the development of new drugs, since they may 
represent an important advance in the treatment of complex diseases such as Alzheimer 
and Parkinson’s diseases. 
Coumarins are a large family of compounds, of both natural and synthetic origin, 
important because of the pharmacological activities that this compounds display. 
Therefore, they occupy an important place in the organic and medicinal chemistry 
realm. In recent years, coumarins have been attracting interest because of their ability of 
inhibiting some enzymes. The versatility of the Perkin and Knoevenagel reactions has 
led to a large family of differently substituted compounds.  
In order to find the structural features for the human MAO inhibitory activity and 
selectivity, in the present communication we report the synthesis, pharmacological 
evaluation and a comparative study of a new series of 3-phenylcoumarins versus 3-
benzoylcoumarins. A bromo atom and a methoxy/hydroxyl substituent were introduced 
in these scaffolds at different positions of the coumarin moiety. The synthesized 
compounds were evaluated as MAO-A and B inhibitors using R-(-)-deprenyl and 
iproniazide as reference compounds. The presence or absence of a carbonyl group 
between the coumarin and the phenyl substituent in 3 position remarks, respectively, the 
MAO-A or MAO-B inhibitory activity. Some of the new compounds showed MAO-B 
inhibitory activities in the low micromolar range.  
In addition, docking experiments were carried out on hMAO-A and h-MAO-B 
structures. This study has provided new information about the enzyme-inhibitor 
interaction and the potential therapeutic application of this coumarin scaffolds. 
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1. Introduction 
Coumarins, stilbenes, chalcone and their natural and/or synthetic derivatives (Figure 
1) are biologically interesting compounds because of their structural diversity. Due to 
this variability, these heterocyclic compounds occupy an important role not only in the 
Organic Chemistry but also in the Medicinal Chemistry realm.1-6 They are described as 
anticancer, anti-inflammatory, antimicrobial and antioxidant agents.7-16 A number of 
studies pay special attention to coumarin derivatives as monoamine oxidase (MAO)17-23 
inhibitors. Recently, chalcone structure has also been identified as a valid scaffold for 
monoamine oxidase inhibitors (MAOI).24 Therefore, recent findings reveal that MAO-A 
and MAO-B affinity and selectivity can be efficiently modulated by appropriate 










Coumarin-chalcone hybrid  
Figure 1. General structures of coumarins, trans-stilbenes, trans-chalcones, coumarin-
stilbene hyvbrids and coumarin-chalcone-hybrids. 
 
MAO is a FAD-containing enzyme (flavoenzyme) bound to the outer mitochondrial 
membrane in neuronal, glial and many other cells.28,29 Two isoforms namely as MAO-A 
and MAO-B have been identified based on their amino acid sequences, three-
dimensional structure, substrate preference and inhibitor selectivity.30,31 These 
isoenzymes are responsible for the oxidative deamination of neurotransmitters and 
dietary amines. Therefore, they are responsible for the regulation of intracellular levels 
of biogenic amines in the brain and the peripheral tissues.32,33 MAO-B preferentially 
deaminates phenylethylamine and benzylamine, while MAO-A has a higher affinity for 
noradrenaline and serotonin.34,35 Despite of these differences, dopamine and tyramine 
are common substrates for both isoforms. These properties determine the 
pharmacological interest of MAOIs. Selective and irreversible MAO-B inhibitors, such 
as selegiline (R-(-)-deprenyl) and rasagiline are useful compounds for the treatment of 
Parkinson 36,37 and Alzheimer’s diseases.38,39 Selective MAO-A inhibitors, such as 
clorgyline (irreversible) and moclobemide (reversible), are useful for the treatment of 
neurological disorders, such as depression and anxiety.40,41 All these findings have led 
us to an intensive search for novel, selective and efficient MAO inhibitors. 
 
2. Chemistry 
With the aim of finding novel and selective MAO-B inhibitors, we have previously 
synthesized 3-arylcoumarin derivatives in which both the coumarin nucleus and a 3-
phenyl ring were differently substituted. The experimental data show that those 
compounds are potent and selective MAO-B inhibitors.20-23 In particular, the 6,8-
disubstituted coumarins proved to be very interesting derivatives.22 Based on the 
previous 3-phenylcoumarins experimental results, in this paper we describe a new 
project with a comparative study between 3-phenylcoumarins (compounds 1-4) and 3-
benzoylcoumarins (compounds 5-8), which are interesting semi-rigid chalcones with the 
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Scheme 1 
 
The 6-bromo-8-methoxycoumarins were efficiently synthesized by Perkin43-45 (1 and 
2) and Knoevenagel46,47 (5 and 6) reactions. The hydroxy derivatives (3, 4, 7 and 8)42 
were obtained by two different hydrolysis reactions,48-50 according to the synthetic 
protocol outlined in scheme 1. Treatment of the corresponding salicylaldehyde and the 
conveniently substituted phenylacetic acid with N,N’-dicyclohexylcarbodiimide (DCC) 
as dehydrating agent, in dimethyl sulfoxide (DMSO) at 110 ºC during 24 hours, 
afforded the 3-phenylcoumarins 1 and 2. The consequent hydrolysis of 1 and 2 in acetic 
acid and acetic anhydride, with hydriodic acid 57 %, for 4 hours, yielded the hydroxy 
derivatives 3 and 4.42 The synthesis of the 3-benzoylcoumarins 5 and 6 was performed 
via condensation of the conveniently substituted salicylaldehyde with the corresponding 
β-ketoester, in ethanol at reflux temperature for 5 or 2 hours respectively, using 
piperidine as basic catalyst. The resulting methoxy derivatives were treated with boron 
tribromide at 80 ºC for 48 hours, to give the corresponding hydroxy derivatives 7 and 8. 
Starting from the same salicylaldehyde, we can afford two series, differing just in the 
presence (compounds 5-8) or absence (compounds 1-4) of a carbonyl group between the 
phenyl ring at the 3 position and the coumarin scaffold.  
3. Results and discussion 
The inhibitory MAO activity of compounds 3, 4, 7 and 8 was evaluated in vitro by 
the measurement of the enzymatic activity of human recombinant MAO isoforms 
expressed in BTI insect cells infected with baculovirus.52 Subsequently, the IC50 values 
and MAO-B selectivity indexes [IC50 (MAO-A)]/[IC50 (MAO-B)] for inhibitory effects 
of both new types of compounds and reference inhibitors were calculated (Table 1).52 
 
Table 1. MAO-A and MAO-B inhibitory activity results for the synthesized compounds 








3 * 30.91±2.09 > 3.2a 
4 20.74±1.40 16.87±1.14 1.2 
7 46.81±3.18 73.92±4.99 0.63 
8 19.17±1.29 ** 0.19b 
R-(-)-Deprenyl 67.25±1.02 19.60x10-3±0.86x10-3 3,431 
Iproniazide 6.56±0.76 7.54±0.36 0.87 
*Inactive at 100 µM (highest concentration tested). At higher concentrations compound precipitate. 
** 100 µM inhibits enzymatic activity around (by approximately) 45-50 %. At higher concentrations 
compound precipitate.  
aValues obtained under the assumption that the corresponding IC50 against MAO-A is the highest 
concentration tested (100 µM). 
bValue obtained under the assumption that the corresponding IC50 against MAO-B is the highest tested 
concentration (100 µM). 
 
In the present communication, the effect of the presence or the absence of a carbonyl 
group between the coumarin and the 3-phenyl ring is studied. Substituents and their 
positions in the 3-phenylcoumarin nucleus have been selected based on previous results 
which showed very high MAOI activity for some derivatives. It was shown that the 
presence of a bromo atom at position 6 and a hydroxyl group at position 8 of the 
coumarin nucleus (compound 3) allows a selective MAO-B compound. When another 
hydroxyl group is included in para position of the 3-aryl ring (compound 4), the MAO-
B selectivity was lost. On the other hand, when we analyze the second series where a 3-
benzoyl group has replaced the 3-phenyl substituent, the introduced carbonyl group 
decreases the MAOI activity against B isoform. Compounds 7 and 8 increase the 
affinity for the MAO-A receptor, losing the MAO-B selectivity of compound 3, from 
the first series. Also, compound 8 is selective against the MAO-A isoenzyme. A small 
change in the structure causes a big change in the affinity of the molecules for the 
receptor. These preliminary results allow us to understand slightly better interactions 
between molecule and receptor and the molecular fragments that are essential to 
maintain and improve the MAO activity and selectivity.  
We try here to rationalize the experimental data by comparing the best docking poses 
of coumarins derivatives into MAO-A (PDB id: 2Z5X) and MAO-B (PDB id: 2V60) 
crystal structures. Best docking poses retrieved for molecules 3, 4, 7 and 8 into MAO-A 
and MAO-B isoforms. Three water molecules are found to be conserved in both MAO 
binding sites. All the water molecules show a H-bonds network with backbone and/or 
side chain residues of the receptor. H-bonds are displayed in yellow dot line. Hidden 
residues for a better visualization: from Thr167 to Ser184 in MAO-A, from Glu159 to 
Val173 in MAO-B.  
Structural water molecules are involved (via H-bonds) in ligand-protein binding 
interactions. The different active site residues in MAO isoforms play a significant role 
in docking pose orientation of coumarins. Therefore, selectivity of compounds 3 and 8 
against MAO-B and MAO-A respectively, might be partially explained taking into 
account the interactions with key residues at the binding cleft. QM-Polarized Ligand 
Docking followed by a post-processing analysis with Prime MM-GBSA has proved to 
be useful to study a congeneric series of compounds. Docking studies with the 
compounds and both isoforms of the MAO enzyme are shown below: 
 
 
Figure 2. Interaction of compounds 3, 4, 7 and 8 with the binding site of MAO-A. 
 
 
Figure 3. Interaction of compounds 3, 4, 7 and 8 with the binding site of MAO-B. 
 
4. Conclusions 
As conclusion, it was verified an important lost of the MAO-B inhibitory activity and 
selectivity when the 3-phenyl skeleton is substituted for the 3-benzoyl one. However, in 
some of the 3-benzoyl derivatives it was shown not only inactivity against MAO-B 
isoenzyme, but showed MAO-A inhibitory activity and selectivity. Therefore, 
selectivity seems to depend on the nature of the coumarins’ substituent. In the present 
study it was shown that 6-bromo-8-methoxy-3-phenylcoumarins are an interesting 
scaffold for MAO-B inhibitory studies, whereas the 6-bromo-8-hydroxy-3-
benzoylcoumarins are an interesting moiety for MAO-A inhibitory ones. The MAO 
selectivity is an important factor to discriminate the different potential therapeutic 
applications of these molecules. These findings encourage us to continue the efforts 
towards the optimization of the pharmacological profile of these structural types as 
important scaffolds in the neurodegenerative diseases realm.  
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